Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew I Milowsky

Showing results (191-200 of 205) with videos related to

Pageof 21
Sort By:
European Urology Oncology|December 21, 2024
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study DataTanya Jindal, Cindy Jiang, Omar Alhalabi, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder CancerDavid J McConkey, Brian C Baumann, Stephanie Cooper Greenberg, et al.
European Urology Open Science|December 22, 2021
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical ProstatectomyKaren A Autio, Emmanuel S Antonarakis, Tina M Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 16, 2020
Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO GuidelineEdouard J Trabulsi, R Bryan Rumble, Hossein Jadvar, et al.
Bladder Cancer (Amsterdam, Netherlands)|March 4, 2025
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer<sup></sup>Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, et al.
Cancer|May 5, 2021
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancerDaniel J George, Susan Halabi, Elisabeth I Heath, et al.
Cancer|December 9, 2021
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) studyVadim S Koshkin, Nicholas Henderson, Marihella James, et al.
The Oncologist|October 7, 2025
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative studyCindy Y Jiang, Hyunsoo Hwang, Ilana Y Epstein, et al.
European Urology|October 12, 2016
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)Andrea Necchi, Guru Sonpavde, Salvatore Lo Vullo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2018
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder CancerGopa Iyer, Arjun V Balar, Matthew I Milowsky, et al.
Pageof 21

Showing results (191-200 of 205) with videos related to

Sort By:
Pageof 21
European Urology Oncology|December 21, 2024
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study DataTanya Jindal, Cindy Jiang, Omar Alhalabi, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder CancerDavid J McConkey, Brian C Baumann, Stephanie Cooper Greenberg, et al.
European Urology Open Science|December 22, 2021
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical ProstatectomyKaren A Autio, Emmanuel S Antonarakis, Tina M Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 16, 2020
Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO GuidelineEdouard J Trabulsi, R Bryan Rumble, Hossein Jadvar, et al.
Bladder Cancer (Amsterdam, Netherlands)|March 4, 2025
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer<sup></sup>Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, et al.
Cancer|May 5, 2021
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancerDaniel J George, Susan Halabi, Elisabeth I Heath, et al.
Cancer|December 9, 2021
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) studyVadim S Koshkin, Nicholas Henderson, Marihella James, et al.
The Oncologist|October 7, 2025
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative studyCindy Y Jiang, Hyunsoo Hwang, Ilana Y Epstein, et al.
European Urology|October 12, 2016
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)Andrea Necchi, Guru Sonpavde, Salvatore Lo Vullo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2018
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder CancerGopa Iyer, Arjun V Balar, Matthew I Milowsky, et al.
Pageof 21